Edward Tenthoff
Stock Analyst at Piper Sandler
(2.20)
# 2,704
Out of 4,876 analysts
177
Total ratings
38.86%
Success rate
-3.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Reiterates: Overweight | $105 | $47.49 | +121.10% | 7 | Jun 27, 2025 | |
| STRO Sutro Biopharma | Upgrades: Overweight | $2 | $0.73 | +172.48% | 7 | Jun 16, 2025 | |
| BMEA Biomea Fusion | Assumes: Overweight | $7 | $1.81 | +286.74% | 1 | Jun 3, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Overweight | $6 → $9 | $7.10 | +26.76% | 4 | May 29, 2025 | |
| ITOS iTeos Therapeutics | Maintains: Overweight | $16 → $12 | $9.95 | +20.60% | 1 | May 14, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | $24 → $14 | $7.54 | +85.68% | 7 | May 2, 2025 | |
| IPSC Century Therapeutics | Maintains: Overweight | $4 → $2 | $0.52 | +285.58% | 8 | Mar 20, 2025 | |
| DYN Dyne Therapeutics | Maintains: Overweight | $53 → $48 | $9.57 | +401.57% | 6 | Feb 28, 2025 | |
| MESO Mesoblast | Reiterates: Overweight | $15 → $24 | $10.91 | +119.98% | 5 | Feb 7, 2025 | |
| LEGN Legend Biotech | Reiterates: Overweight | $78 | $34.63 | +125.24% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $8.14 | +268.55% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $45 | $16.08 | +179.85% | 11 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $296 | $322.83 | -8.31% | 13 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $115 → $69 | $27.16 | +154.05% | 12 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $6.90 | +842.03% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $1.52 | +1,084.21% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $11.15 | +213.90% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $4.11 | +386.62% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.32 | +127.27% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.74 | +304.86% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $4.60 | +247.83% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.04 | +476.92% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.86 | +168.82% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $56 | $44.12 | +26.93% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $224 → $248 | $8.43 | +2,841.87% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.83 | +4,818.03% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $6 | $0.45 | +1,233.33% | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $9.10 | +1,878.02% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $17.08 | +157.61% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $7.24 | +411.05% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $2,246,640 → $651,200 | $3.08 | +21,142,757.14% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $560.14 | -36.80% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.22 | +10,965.57% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $441.30 | -26.81% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $43.67 | -17.56% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.47 | +1,600.68% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.92 | +16,202.58% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $53 | $1.08 | +4,807.41% | 2 | Jan 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,380 | $0.60 | +230,283.97% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $521.00 | - | 11 | Feb 13, 2017 |
CRISPR Therapeutics AG
Jun 27, 2025
Reiterates: Overweight
Price Target: $105
Current: $47.49
Upside: +121.10%
Sutro Biopharma
Jun 16, 2025
Upgrades: Overweight
Price Target: $2
Current: $0.73
Upside: +172.48%
Biomea Fusion
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.81
Upside: +286.74%
Fulcrum Therapeutics
May 29, 2025
Maintains: Overweight
Price Target: $6 → $9
Current: $7.10
Upside: +26.76%
iTeos Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $9.95
Upside: +20.60%
Arvinas
May 2, 2025
Reiterates: Overweight
Price Target: $24 → $14
Current: $7.54
Upside: +85.68%
Century Therapeutics
Mar 20, 2025
Maintains: Overweight
Price Target: $4 → $2
Current: $0.52
Upside: +285.58%
Dyne Therapeutics
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $9.57
Upside: +401.57%
Mesoblast
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $10.91
Upside: +119.98%
Legend Biotech
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $34.63
Upside: +125.24%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $8.14
Upside: +268.55%
Nov 27, 2024
Maintains: Overweight
Price Target: $62 → $45
Current: $16.08
Upside: +179.85%
Nov 18, 2024
Reiterates: Overweight
Price Target: $296
Current: $322.83
Upside: -8.31%
Nov 18, 2024
Reiterates: Overweight
Price Target: $115 → $69
Current: $27.16
Upside: +154.05%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $6.90
Upside: +842.03%
Nov 5, 2024
Initiates: Overweight
Price Target: $18
Current: $1.52
Upside: +1,084.21%
Oct 21, 2024
Initiates: Overweight
Price Target: $35
Current: $11.15
Upside: +213.90%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $4.11
Upside: +386.62%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.32
Upside: +127.27%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.74
Upside: +304.86%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $4.60
Upside: +247.83%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.04
Upside: +476.92%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.86
Upside: +168.82%
Feb 27, 2024
Maintains: Overweight
Price Target: $39 → $56
Current: $44.12
Upside: +26.93%
Aug 14, 2023
Maintains: Overweight
Price Target: $224 → $248
Current: $8.43
Upside: +2,841.87%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $1.83
Upside: +4,818.03%
Nov 4, 2022
Maintains: Overweight
Price Target: $13 → $6
Current: $0.45
Upside: +1,233.33%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $9.10
Upside: +1,878.02%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $17.08
Upside: +157.61%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $7.24
Upside: +411.05%
May 13, 2022
Maintains: Overweight
Price Target: $2,246,640 → $651,200
Current: $3.08
Upside: +21,142,757.14%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $560.14
Upside: -36.80%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.22
Upside: +10,965.57%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $441.30
Upside: -26.81%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $43.67
Upside: -17.56%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.47
Upside: +1,600.68%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.92
Upside: +16,202.58%
Jan 6, 2020
Maintains: Overweight
Price Target: $26 → $53
Current: $1.08
Upside: +4,807.41%
Dec 11, 2017
Initiates: Overweight
Price Target: $1,380
Current: $0.60
Upside: +230,283.97%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $521.00
Upside: -